Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation

Juan Viles Gonzalez, Davendra Mehta

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Periprocedural thromboembolic and hemorrhagic events are complications of percutaneous radiofrequency catheter ablation (RFA) of atrial fibrillation (AF). The management of anticoagulation before and after RFA could play an important role in the prevention of these complications. The incidence of thromboembolic events varies from 1% to 5%, depending on the ablation and the anticoagulation strategy used in the periprocedural period. The scientific evidence behind the management of anticoagulation in patients with AF undergoing RFA is scarce and is mostly based on small studies and experts' consensus. It remains unclear whether catheter ablation for AF reduces the risk of stroke and obviates the need for anticoagulation after the procedure. Limited data are available regarding the risk of thromboembolism with and without warfarin after AF ablation. In this review we will review the most current evidence supporting the different strategies to reduce thromboembolic risk before, during, and after catheter ablation for AF.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalCurrent Cardiology Reports
Volume13
Issue number1
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Catheter Ablation
Atrial Fibrillation
Thromboembolism
Warfarin
Stroke
Incidence

Keywords

  • Ablation
  • Anticoagulation
  • Atrial fibrillation
  • Catheter
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation. / Viles Gonzalez, Juan; Mehta, Davendra.

In: Current Cardiology Reports, Vol. 13, No. 1, 01.02.2011, p. 38-42.

Research output: Contribution to journalArticle

@article{b8769ea08962473f974bdaf0e2121348,
title = "Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation",
abstract = "Periprocedural thromboembolic and hemorrhagic events are complications of percutaneous radiofrequency catheter ablation (RFA) of atrial fibrillation (AF). The management of anticoagulation before and after RFA could play an important role in the prevention of these complications. The incidence of thromboembolic events varies from 1{\%} to 5{\%}, depending on the ablation and the anticoagulation strategy used in the periprocedural period. The scientific evidence behind the management of anticoagulation in patients with AF undergoing RFA is scarce and is mostly based on small studies and experts' consensus. It remains unclear whether catheter ablation for AF reduces the risk of stroke and obviates the need for anticoagulation after the procedure. Limited data are available regarding the risk of thromboembolism with and without warfarin after AF ablation. In this review we will review the most current evidence supporting the different strategies to reduce thromboembolic risk before, during, and after catheter ablation for AF.",
keywords = "Ablation, Anticoagulation, Atrial fibrillation, Catheter, Stroke",
author = "{Viles Gonzalez}, Juan and Davendra Mehta",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s11886-010-0153-2",
language = "English",
volume = "13",
pages = "38--42",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation

AU - Viles Gonzalez, Juan

AU - Mehta, Davendra

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Periprocedural thromboembolic and hemorrhagic events are complications of percutaneous radiofrequency catheter ablation (RFA) of atrial fibrillation (AF). The management of anticoagulation before and after RFA could play an important role in the prevention of these complications. The incidence of thromboembolic events varies from 1% to 5%, depending on the ablation and the anticoagulation strategy used in the periprocedural period. The scientific evidence behind the management of anticoagulation in patients with AF undergoing RFA is scarce and is mostly based on small studies and experts' consensus. It remains unclear whether catheter ablation for AF reduces the risk of stroke and obviates the need for anticoagulation after the procedure. Limited data are available regarding the risk of thromboembolism with and without warfarin after AF ablation. In this review we will review the most current evidence supporting the different strategies to reduce thromboembolic risk before, during, and after catheter ablation for AF.

AB - Periprocedural thromboembolic and hemorrhagic events are complications of percutaneous radiofrequency catheter ablation (RFA) of atrial fibrillation (AF). The management of anticoagulation before and after RFA could play an important role in the prevention of these complications. The incidence of thromboembolic events varies from 1% to 5%, depending on the ablation and the anticoagulation strategy used in the periprocedural period. The scientific evidence behind the management of anticoagulation in patients with AF undergoing RFA is scarce and is mostly based on small studies and experts' consensus. It remains unclear whether catheter ablation for AF reduces the risk of stroke and obviates the need for anticoagulation after the procedure. Limited data are available regarding the risk of thromboembolism with and without warfarin after AF ablation. In this review we will review the most current evidence supporting the different strategies to reduce thromboembolic risk before, during, and after catheter ablation for AF.

KW - Ablation

KW - Anticoagulation

KW - Atrial fibrillation

KW - Catheter

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=79551577309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551577309&partnerID=8YFLogxK

U2 - 10.1007/s11886-010-0153-2

DO - 10.1007/s11886-010-0153-2

M3 - Article

C2 - 21057900

AN - SCOPUS:79551577309

VL - 13

SP - 38

EP - 42

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 1

ER -